OVIT (OncoVista Innovative Therapies) Liabilities-to-Assets : 109.03 (As of Sep. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoVista Innovative Therapies Liabilities-to-Assets?

OncoVista Innovative Therapies OVIT Liabilities-to-Assets is 109.03 as of Sep. 2015.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. OncoVista Innovative Therapies's Total Liabilities for the quarter that ended in Sep. 2015 was $6.65 Mil. OncoVista Innovative Therapies's Total Assets for the quarter that ended in Sep. 2015 was $0.06 Mil. Therefore, OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2015 was 109.03.

OncoVista Innovative Therapies  (OTCPK:OVIT) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

OncoVista Innovative Therapies Liabilities-to-Assets Related Terms

OncoVista Innovative Therapies Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for OncoVista Innovative Therapies's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoVista Innovative Therapies Liabilities-to-Assets Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 1.06 3.92 33.50 436.62

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.39 436.62 107.09 252.32 109.03

OVIT vs RSPI, HSTC, CAPS: Liabilities-to-Assets Comparison

For the Biotechnology subindustry, OncoVista Innovative Therapies's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoVista Innovative Therapies Liabilities-to-Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's Liabilities-to-Assets falls into.


OncoVista Innovative Therapies Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2014 is calculated as:

Liabilities-to-Assets (A: Dec. 2014 )=Total Liabilities/Total Assets
=5.676/0.013
=436.62

OncoVista Innovative Therapies's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2015 is calculated as

Liabilities-to-Assets (Q: Sep. 2015 )=Total Liabilities/Total Assets
=6.651/0.061
=109.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 109.03 mean?
OncoVista Innovative Therapies (OVIT) has a Liabilities-to-Assets of 109.03 as of Sep. 2015. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on OncoVista Innovative Therapies and its competitors.
Is OncoVista Innovative Therapies' Liabilities-to-Assets too high?
OncoVista Innovative Therapies' current Liabilities-to-Assets is 109.03.
How does OncoVista Innovative Therapies' Liabilities-to-Assets compare to RSPI and HSTC?
OncoVista Innovative Therapies' Liabilities-to-Assets of 109.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Biotechnology company?
A good Liabilities-to-Assets depends on the Biotechnology industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on OncoVista Innovative Therapies and its competitors. OncoVista Innovative Therapies's current Liabilities-to-Assets is 109.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoVista Innovative Therapies stock overvalued right now?
OncoVista Innovative Therapies (OVIT) has a current Liabilities-to-Assets of 109.03. The current Liabilities-to-Assets is 109.03. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For OncoVista Innovative Therapies (OVIT), the current Liabilities-to-Assets is 109.03 as of Sep. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoVista Innovative Therapies Business Description

Address 14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.